Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis
出版年份 2023 全文链接
标题
Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis
作者
关键词
-
出版物
Diabetology & Metabolic Syndrome
Volume 15, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-10-28
DOI
10.1186/s13098-023-01195-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
- (2023) Xiaoyi Chen et al. Frontiers in Pharmacology
- Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice
- (2022) Beatriz Aviles Bueno et al. Clinical Kidney Journal
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2022) Melanie J. Davies et al. DIABETOLOGIA
- The Combined Intervention of Aqua Exercise and Burdock Extract Synergistically Improved Arterial Stiffness: A Randomized, Double-Blind, Controlled Trial
- (2022) Min-Seong Ha et al. Metabolites
- Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
- (2021) Salim S. Virani et al. CIRCULATION
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
- (2021) Julie R. Lundgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
- (2021) Sean Wharton et al. DIABETES OBESITY & METABOLISM
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole‑kindled mice
- (2021) Lei Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Epigenetic regulation of insulin action and secretion – role in the pathogenesis of type 2 diabetes
- (2020) C. Ling JOURNAL OF INTERNAL MEDICINE
- Assessment of Incidence and Risk Factors of Intracerebral Hemorrhage Among Participants in the Framingham Heart Study Between 1948 and 2016
- (2020) Vasileios-Arsenios Lioutas et al. JAMA Neurology
- Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease
- (2020) Michael C. Honigberg et al. JAMA Cardiology
- Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
- (2020) Mansoor Husain et al. Cardiovascular Diabetology
- Efficacy and safety of once‐weekly semaglutide vs once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes ( SUSTAIN China): a 30‐week double‐blind, phase 3a, randomised trial
- (2020) Linong Ji et al. DIABETES OBESITY & METABOLISM
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
- (2019) V. R Aroda et al. DIABETES & METABOLISM
- Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
- (2019) Bernard Zinman et al. Lancet Diabetes & Endocrinology
- The Future of the GLP-1 Receptor Agonists
- (2019) Irl B. Hirsch JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
- (2019) M.S. Capehorn et al. DIABETES & METABOLISM
- Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
- (2019) Ildiko Lingvay et al. Lancet Diabetes & Endocrinology
- A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin
- (2018) Ildiko Lingvay et al. DIABETES CARE
- Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
- (2018) Kohei Kaku et al. DIABETES OBESITY & METABOLISM
- Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis
- (2018) Panagiotis Andreadis et al. DIABETES OBESITY & METABOLISM
- Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
- (2018) Helena W Rodbard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2018) Fang-Hong Shi et al. Frontiers in Pharmacology
- Precision medicine in the management of type 2 diabetes
- (2018) Anna L Gloyn et al. Lancet Diabetes & Endocrinology
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis
- (2018) Mishriky B.M. et al. DIABETES & METABOLISM
- Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy
- (2018) Antonios Douros et al. DIABETES CARE
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- (2017) Bo Ahrén et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- (2017) Christopher Sorli et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- (2017) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
- (2015) Michael A. Nauck et al. DIABETES CARE
- Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
- (2015) Feng Sun et al. Diabetes Technology & Therapeutics
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
- (2013) David M. Nathan et al. DIABETES CARE
- Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
- (2013) L van Bloemendaal et al. JOURNAL OF ENDOCRINOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started